Fig. 2From: Small molecule drug development for rare genodermatoses – evaluation of the current status in epidermolysis bullosaSummary of distribution of EB subtypes, outcome measures and routes of administration in reviewed trials. Percentage of respective parameters (a. EB subtype. b. outcome measure, c. route of administration) is given. A total of > 100% derives from the fact, that some studies have multiple specifications per criteria (e.g. outcome measure: wound healing and reduction of pain)Back to article page